A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

Thomas E. Witzig, Gregory A. Wiseman, Matthew J. Maurer, Thomas M. Habermann, Ivana N.M. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Joseph P. Colgan, David J. Inwards, Luis F. Porrata, Brian K. Link, Clive S. Zent, Patrick B. Johnston, Tait D. Shanafelt, Cristine Allmer, Yan W. Asmann, Mamta Gupta, Zuhair K. Ballas, Brian J. Smith, George J. Weiner

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and <sup>90</sup>yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences